Hansen Gwenn sold $100K of NRIX

Nurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.

Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a corporate update. It entered a global Roche collaboration for bexobrutideg (NX-5948) with up to $2.3B total payments, including a $700M upfront. Nurix said EHA data showed CLL/SLL ORR of 83% (PFS 22.1 months) and cash of $443.5M as of May 31, 2026.

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nrix-20260709xexx991.htm EX-99.1 Document Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3

Nurix Therapeutics (NRIX) extended gains for an eighth straight session, reaching a 52-week high of $23.09 and closing up 16.37% at $22.46, according to trading data cited in the article. The move followed Nurix’s partnership with Roche to co-develop and commercialize bexobrutideg, with $700 million upfront and up to $2.3 billion in milestones, the companies said.

Markets settled higher as inflation expectations eased; the 10-year breakeven rate fell to 2.452%. European yields rose, with Germany’s 10-year Bund at 3.060% (+2.2 bp) and UK gilt at 4.943% (+4.0 bp). Eurozone Sentix confidence improved to -3.4. Chipmakers rallied: Intel +11% after Google ordered 3 million Tensor Processing Units for 2028; others also gained.

Redmile Group, LLC purchased 400,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($6.80M total) on 2026-08-06.